UBS Group
AUPH icon

UBS Group’s Aurinia Pharmaceuticals AUPH Stock Holding History

UBS Group’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-10,000
Closed -$221K – 10240
2021
Q3 		$221K Buy
+10,000
New +$159K ﹤0.01% 5235

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group's AUPH Position: Q2 2026 in Review

UBS Group reduced its Aurinia Pharmaceuticals (AUPH) stake by 50% in Q2 2026, selling an estimated $3.1M and leaving 191,600 shares worth $3.25M. The position accounts for ﹤0.01% of the portfolio, ranked #4613.

UBS Group first reported a position in AUPH in Q4 2015 and has held it in 42 quarters since. The position peaked at $5.72M in Q1 2026. 283 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • UBS Group held 191,600 shares of Aurinia Pharmaceuticals worth $3.25M as of Q2 2026.
  • UBS Group sold 194,256 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $3.1M.
  • Aurinia Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4613 holding.
  • UBS Group first reported a position in Aurinia Pharmaceuticals in Q4 2015 and has held it in 42 quarters since.
  • UBS Group's Aurinia Pharmaceuticals position peaked at $5.72M in Q1 2026.
  • 283 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.